Nuvation Bio Inc. NUVB
Analyst Ratings
- Consensus
- Buy — 8 Buy · 1 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $13.00 (+99.7% upside)
Key Stats
- Today's Range
- $6.44 – $6.77
- 50-Day Range
- $4.45 – $6.79
- 52-Week Range
- $2.06 – $9.75
- Volume
- 1.29 million shs
- Average Volume
- 6.07 million shs
- Market Cap
- $2.18 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 8.60
- Price / Sales
- 12.85
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $169.90 million
- Net Income
- $-149,827,000
- Net Margin
- -88.19%
- Return on Equity
- -59.02%
- Debt-to-Equity
- 0.96
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Related Stocks
Compare head-to-head: NUVB vs LLY·NUVB vs JNJ·NUVB vs ABBV·NUVB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.